Unyango lwe-HIV kwaSirayeli - Effective AIDS Treatment Kwelinye

unyango lwe-HIV kwaSirayeli kukuqinisekisa ukuba abantu abane-HIV banokuphila ubomi obuqhelekileyo. Amachiza Anti-HIV asebenza ngokunciphisa umthamo we-HIV egazini umthamo wentsholongwane egazini. Injongo unyango lwe-HIV: umthamo wentsholongwane egazini. Oku kuthetha ukuba emva kokuba unyango lwe-HIV phesheya, umthamo we-HIV egazini incinane kangangokuba akakwazi ukubonwa iimvavanyo eqhelekileyo. Ukunciphisa umthamo we-HIV egazini kunceda ukomeleza amajoni omzimba. Uphakamile i-CD4 cell count, inowuthi umngcipheko wezifo ngenxa usuleleko yi-HIV, mhlawumbi ezinye izigulo ezinzulu.

Kufuneka uxoxe elona xesha lifanelekileyo nogqirha wakho ukuba ukuqala unyango lwe-HIV amazwe. Kukho iqela lemiba ukuba ungafuna ukuqwalasela, kuquka: Indzuzo ukuqala unyango ngeli xesha. nobungozi, ukuba kukho ukulibaziseka kokuqalisa unyango. Ingaba ukulungele na ukuqala unyango ngoku? Kukho ezinye izinto ebomini bakho echaphazela ubuchule kunye nemfuneko ukuqala unyango AIDS kwaSirayeli.

Kwiimeko ezininzi, sincoma ikhosi epheleleyo unyango lwalo naluphi na usuleleko phambi kokuba uqale unyango lwe-HIV. Ukuba CD4 count malunga 350, kucetyiswa ukuba ukuxoxa unyango lwe-HIV kunye nogqirha wakho kwaye uqale unyango lwe-HIV kwaSirayeli, kamsinya nje sele ukulungele. Ezinye izigulane mabacetyiswe ukuba ukuqala unyango xa CD4 yazo cell count nangoku ngaphezulu kwama-350, umzekelo, abantu hepatitis B okanye hepatitis C. Elinye iqela labantu uqale unyango msinyane zezo nge HIV rhesus negative. Oku kwenziwa kukuba unyango lwe-AIDS kunciphisa ngokubanzi umthwalo wentsholongwane kwaye kucutha umngcipheko wokosuleleka yintsholongwane kaGawulayo.

Unyango eqhelekileyo kubantu ukuba unyango HIV okwesihlandlo sokuqala ludibaniso amachiza amathathu. Amachiza Anti-HIV bangamalungu kwiiklasi ezahlukeneyo, ngokuxhomekeke umsebenzi wabo kwi-HIV. iiklasi ezintathu ezinkulu amachiza alwa ne-HIV: analogue reverse transcriptase inhibitors (NRTI), non-analogue inhibitors reverse transcriptase (NNRTIs) kunye ritonavir-protease inhibitors. Kukhethwa, ukuhlanganiswa amachiza alwa ne-HIV kubantu abathatha unyango lwe-HIV okokuqala yi NNRTI-efavirenz (Sustiva) okanye NRTI tenofovir (whoonga) kunye FTC (emtricitabine, Emtriva) kunye 3TC (lamivudine, Epivir) kunye abacavir (Ziagen).

FTC, ne-TDF zidibene wabiza iipilisi Truvada. 3TC (lamivudine, Epivir) kunye abacavir (Ziagen) Epzicom iqukwe cwecwe. Phambi kokuba uthathe Kivexa kufuneka benze uvavanyo lwegazi ukuqinisekisa akukho aleji abacavir. Kivexa inokuba ukhetho elungileyo, ukuba kukho ingozi yesifo sentliziyo. Kwaye tenofovir ayikwazi kuba ukhetho olungileyo xa uneengxaki zezintso. Ukuba uthathe i-efavirenz, tenofovir kunye FTC, kamsinya nje ekwindla umthamo wentsholongwane egazini ubuncinane kangangeenyanga ezintandathu, uyakwazi ukukheta ukuya uthabathe zontathu ezi iziyobisi elucwecweni zidityaniswe ebizwa Atripla.

Elinye efavirenz, ritonavir, i inhibitor protease. Kubalilapo protease inhibitor inokuba yindlela elungileyo ukuba yokunganyangeki ngamachiza kwe-HIV kufuneka NNRTIs kunye NRTI. Ethandwayo na protease inhibitors lopinavir, atazanavir (Reyataz), darunavir (Presista), fosamprenavir (Telzir) okanye saquinavir (Invirase). Zonke ezi protease inhibitors kunyuke nge idosi elahlukileyo ritonavir, lopinavir ngaphandle kufumaneka kuphela emacwecweni xa zidityaniswe ne-ritonavir (Kaletra). Integrase inhibitor raltegravir (Isentress), kunye inhibitors ka-CCR5 receptor maraviroc (Celsentri) Kwakhona ezivunyiweyo abantu ukuba unyango HIV amazwe.

Abasetyhini akukhuthazwa ukuba uqale ukuthatha i-nevirapine xa iseli zabo ze-CD4 count mkhulu kwama-250 ngenxa umngcipheko nemiphumela emibi kakhulu. AZT kunye 3TC (Combivir) akunconywa njengokuba ezinye iimveliso ezimbini kwabasetyhini uceba ukukhulelwa. La machiza amathathu ziyacetyiswa ngexesha lokukhulelwa, ngokuba baye babonisa ukuba ukuziphendulela elungileyo ukuthintela usulelo lwe Martyr Great ukusuka kumama ukuya emntwaneni.